Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

Neurology
V H J M TriebelsMartin J van den Bent

Abstract

The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma. The genotype of the tumors was assessed with fluorescent in situ hybridization with locus specific probes for the region 1p36. Four of the 24 patients responded (17%). Fifty percent of patients were still free from progression at 6 months and 21% were free from progression at 12 months. Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy.

Citations

Jan 25, 2013·Current Treatment Options in Neurology·Mairéad G McNamaraWarren P Mason
Nov 24, 2006·The Neurologist·Andrew D Norden, Patrick Y Wen
Oct 2, 2007·Current Opinion in Oncology·Dieta Brandsma, Martin J van den Bent
Dec 9, 2008·The Cancer Journal·Gregory Cairncross, Robert Jenkins
Jun 28, 2007·Current Oncology·W P MasonUNKNOWN Canadian GBM Recommendations Committee
May 27, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·G SimonettiA Silvani
May 4, 2005·Current Neurology and Neuroscience Reports·Roger StuppMonika E Hegi
Nov 16, 2004·Current Opinion in Neurology·M J van den Bent
Nov 11, 2005·Current Opinion in Neurology·Joachim M Baehring
Nov 21, 2007·Expert Review of Anticancer Therapy·Andrew ChiPatrick Y Wen
Aug 24, 2006·Expert Review of Anticancer Therapy·Nicole Mutter, Roger Stupp
Oct 12, 2010·Expert Review of Neurotherapeutics·Marc C Chamberlain
Oct 18, 2007·Expert Review of Neurotherapeutics·Riccardo SoffiettiRoberta Rudà
Aug 12, 2009·Expert Opinion on Pharmacotherapy·Maurizio SalvatiAlessandro Frati
Aug 2, 2012·Cancer Treatment Reviews·Nawale Hajjaji, Philippe Bougnoux
Jul 17, 2012·Hematology/oncology Clinics of North America·Nicholas A Blondin, Kevin P Becker
Dec 19, 2008·Pharmacology & Therapeutics·Nina F Schor
Oct 30, 2007·Neurologic Clinics·Martin J van den Bent
Mar 29, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C LebrunM Frenay
Feb 15, 2008·Critical Reviews in Oncology/hematology·Martin J Van den BentCharles Vecht
Aug 18, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mathilde C M KouwenhovenMartin J van den Bent
Jan 24, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Martin J van den BentRoger Stupp
Apr 24, 2015·CNS Oncology·Walter TaalMartin J van den Bent
Mar 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kurt A JaeckleJan C Buckner
Feb 3, 2009·The Oncologist·Jacolien E C Bromberg, Martin J van den Bent
Feb 16, 2006·The Oncologist·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 15, 2007·Journal of Neuro-oncology·Marie Pierre SunyachDidier Frappaz
May 16, 2008·Journal of Neuro-oncology·Marc C Chamberlain, Michael J Glantz
Jul 27, 2017·The Cochrane Database of Systematic Reviews·Saurabh ParasramkaJohn L Villano
Feb 19, 2005·Journal of Neuro-oncology·Joachim M Baehring
Nov 6, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Louis Burt NaborsSusan D Darlow
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Santosh KesariPatrick Y Wen
Mar 21, 2021·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Chafik HandisM Memet Özek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.